Anti-PD-1 Monotherapy in Advanced Melanoma—Real-World Data from a 77-Month-Long Retrospective Observational Study

Anti-PD-1 Monotherapy in Advanced Melanoma—Real-World Data from a 77-Month-Long Retrospective Observational Study

Real-world evidence plays an important role in the assessment of efficacy and safety of novel therapies. The increasing use of immune checkpoint inhibitors (ICIs) in patients with advanced melanoma has led to notably improved clinical outcomes, while they are also associated with immune-related adve...

Full description

Bibliographic Details
Main Authors: Daniella Kuzmanovszki, Norbert Kiss, Béla Tóth, Tünde Kerner, Veronika Tóth, József Szakonyi, Kende Lőrincz, Judit Hársing, Eleonóra Imrédi, Alexa Pfund, Ákos Szabó, Valentin Brodszky, Fanni Rencz, Péter Holló
Format: Article
Language:English
Published: MDPI AG 2022-07-01
Series:Biomedicines
Subjects:
anti-PD-1 monotherapy
nivolumab
pembrolizumab
advanced melanoma
immune checkpoint inhibitor
adverse event
Online Access:https://www.mdpi.com/2227-9059/10/7/1737

Internet

https://www.mdpi.com/2227-9059/10/7/1737

Similar Items